Collectively, the data presented herein greatly extend our earlier observations of the relevance of treating influenza-induced ALI with TLR4 antagonists (12, –, 15) by further providing a rational therapeutic approach to ameliorate the lethal effects of the 2° bacterial pneumonia that often follows influenza virus infection. Here, TLR4 is linked to acute respiratory distress syndrome.